Introduction
Cease Smoking Today (CS2day) is a nine-partner collaborative designed to reduce the number of persons who smoke and decrease morbidity and mortality from smoking-related illness. Physician assistants often are the primary point of care for many patients, allowing them to focus on health promotion and disease prevention.
This activity is designed to support physician assistants as they help their patients quit smoking. Utilizing clinical case vignettes, an audience response system, and lectures, the discussion will focus on the most relevant applications of the Clinical Practice Guideline: Treating Tobacco Use and Dependence 2008 Update, including pharmacologic and nonpharmacologic treatment options for smoking cessation and practical tools and resources to assist patients to quit smoking and remain tobacco free.FDA Alert
Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics) [7/1/2009]:
FDA has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. The same changes to the prescribing information and Medication Guide for patients will also be required for bupropion products (Wellbutrin and generics) that are indicated for the treatment of depression and seasonal affective disorder. For further details on these important warnings, click here.
On the Front Lines: Assisting Your Patients to Quit Smoking
Powerpoint Slides
For your convenience, the powerpoint slides for this presentation may be downloaded by clicking here.
CME Credit
This program has been reviewed and is approved for 2.5 hours of AAPA Category I CME Credit. After viewing the webcast AAPA Fellow members may complete the post-test by clicking here. Expiration Date: August 2010.
Learning Objectives
Upon completion of the activity, participants should be able to:
- Apply proven strategies from the Clinical Practice Guideline: Treating Tobacco Use and Dependence 2008 Update for screening, motivating, and supporting patients in efforts to quit smoking.
- Integrate appropriate pharmacologic and nonpharmacologic interventions to provide patients with a comprehensive approach to smoking cessation.
- Manage smoking cessation using a chronic disease model approach with patients.
- Integrate smoking cessation into routine care within the clinical practice setting.
Faculty/Presenter Info
Welcome and Overview
Mary P. Ettari, MPH, PA-C
Activity Chairperson
Physician Assistant,
Jensen Beach, Florida
Getting Patients to Consider Quitting: The Why and the How
Mary P. Ettari, MPH, PA-C
Activity Chairperson
Evidence-Based Approaches to Smoking Cessation
Daryl L. Sharp, PhD, NPP, CS, FNAP
Associate Professor of Clinical Nursing,
University of Rochester
School of Nursing
Rochester, New York
A Comprehensive, Long-Term Approach to Smoking Cessation: Patient and Practice Considerations
Cheri L. Olson, MD
Associate Professor,
Mayo School of Graduate Medical Education College of Medicine
Rochester, Minnesota
Associate Director,
La Crosse-Mayo Family Medicine Residency
La Crosse, Wisconsin
Faculty Disclosure Statement
The faculty reported the following:
Mary P. Ettari, MPH, PA-C, has no relevant relationships to disclose in regard to this activity.
Daryl L. Sharp, PhD, NPP, CS, FNAP, has no relevant relationships to disclose in regard to this activity.
Cheri L. Olson, MD, has no relevant relationships to disclose in regard to this activity.
CME Enterprise
All staff and content reviewers involved with the planning and content of this activity have reported no actual or potential conflicts of interest in regard to this activity.
Ms. Ettari's presentation will not include off-label or unapproved uses of drugs.
Dr. Sharp's presentation will include off-label or unapproved uses of drugs.
Dr. Olson's presentation will include off-label or unapproved uses of drugs.
Statement of commercial support
This program was supported by an educational grant from Pfizer.
